HGT-1110
HGT-MLD-071
Phase 2 mab completed
Quick answer
HGT-1110 for Metachromatic Leukodystrophy (MLD) is a Phase 2 program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Metachromatic Leukodystrophy (MLD)
- Phase
- Phase 2
- Modality
- mab
- Status
- completed